Key Takeaways RCKT posted Q4 loss of 38 cents per share, beating estimates, while no revenues were reported.Rocket Pharmaceuticals' resubmitted BLA for Kresladi in LAD-I faces an FDA decision on March 28, 2026.RCKT expects cash runway into Q2 2027 as the RP-A501 study in Danon disease resumes in H1 2026.Rocket Pharmaceuticals (RCKT) incurred a loss of 38 cents per share in the fourth quarter of 2025, which was narrower than the Zacks Consensus Estimate of a loss of 42 cents. In the year-ago quarter, the com ...

Core Insights - Puma Biotechnology (PBYI) reported fourth-quarter 2025 adjusted earnings of 29 cents per share, exceeding the Zacks Consensus Estimate of 24 cents, but down from 43 cents in the same quarter last year [1] - Total revenues for the fourth quarter reached $75.5 million, surpassing the Zacks Consensus Estimate of $68 million, and reflecting a 28% year-over-year increase [2] Financial Performance - Product revenues from Nerlynx totaled $59.9 million in Q4, up nearly 10% year over year, beating estimates of $54 million [4] - Royalty revenues surged 232% year over year to $15.6 million [4] - Total operating costs for the quarter were $58.4 million, an increase of 28% year over year [4] - For the full year 2025, total revenues were $228.4 million, slightly down from $230.5 million in the previous year [6] Guidance and Projections - For 2026, net product revenues are projected to be between $194 million and $198 million, with total revenues expected to range from $214 million to $221 million, which is below the Zacks Consensus Estimate of $235.7 million [7][8] - The company anticipates a net loss of approximately $8 million to $10 million for Q1 2026 [12] Pipeline Developments - Puma Biotechnology is developing alisertib, an aurora kinase A inhibitor, for hormone receptor-positive breast cancer and small-cell lung cancer [13] - The company is conducting a phase II study (ALISCA-Lung1) for alisertib as a monotherapy for extensive-stage SCLC, with interim data expected in Q2 2026 [14] - Another phase II study (ALISCA-Breast1) is underway for alisertib in combination with endocrine treatment for HER2-negative, hormone receptor-positive metastatic breast cancer, with initial data also expected in Q2 2026 [15] Market Performance - PBYI's shares have increased by 154.2% over the past year, compared to the industry's rise of 19.9% [9]

Key Takeaways Perrigo's Q4 EPS fell 17.2% to 77 cents as Infant Formula weakness hit sales and margins.PRGO guided All In 2026 sales down 1.5%-5.5% and EPS of $2.00-$2.30, below expectations.Perrigo will restructure into Self Care, Specialty Care and Infant Formula segments in 2026.Perrigo (PRGO) reported adjusted earnings per share (EPS) of 77 cents for the fourth quarter of 2025, which missed the Zacks Consensus Estimate of 80 cents. The reported figure decreased 17.2% year over year, primarily due to hea ...

Key Takeaways TG Therapeutics reported Q4 EPS of 14 cents, missing estimates despite 78% revenue growth.Briumvi recorded $189.1M in Q4 revenues, with U.S. net sales rising 76% Y/Y and 20% sequentially.TGTX reaffirmed 2026 revenue guidance of $875M-$900M, with Briumvi sales expected to be $825-$850M.TG Therapeutics (TGTX) reported earnings of 14 cents per share for the fourth quarter of 2025, which substantially missed the Zacks Consensus Estimate of 35 cents. The company had reported earnings of 15 cents pe ...

Core Insights - Kymera Therapeutics (KYMR) reported a wider fourth-quarter 2025 loss of 97 cents per share, exceeding the Zacks Consensus Estimate of a loss of 77 cents, and a deterioration from a loss of 88 cents per share in the same quarter last year [1][7] - The company's collaboration revenues were $2.9 million, significantly below the Zacks Consensus Estimate of $30 million, and down from $7.4 million in the year-ago quarter [2][5] - Kymera's shares have increased by 214.2% over the past year, outperforming the industry average rise of 18.6% [2] Financial Performance - Research and development (R&D) expenses rose to $83.8 million, a 16.7% increase year over year, driven by investments in the STAT6 program and other discovery initiatives [3][14] - General and administrative expenses increased by 3.7% year over year to $16.9 million, influenced by higher legal and professional service fees, as well as increased personnel and facility costs [4] - For the full year 2025, revenues decreased by 16.8% to $39.2 million, missing the Zacks Consensus Estimate of $54.7 million, while loss per share increased to $3.69 from $2.98 in 2024 [5] Capital and Funding - In December 2025, Kymera completed an underwritten equity offering that generated approximately $692 million in gross proceeds, raising year-end cash to about $1.6 billion and extending the cash runway into 2029 [4][14] Pipeline Developments - Kymera is advancing its targeted protein degradation (TPD) strategy, with KT-621 in phase 2 development for atopic dermatitis and asthma, showing promising results in recent studies [8][9] - The BROADEN2 phase IIb study for KT-621 has been expanded to include adolescents, with data expected from mid- to late-2027 [10] - KT-579, an oral IRF5 degrader, has begun phase 1 trials following FDA clearance, with results anticipated in the second half of 2026 [11] - The partnered program KT-485/SAR447971 is expected to enter clinical trials in 2026, while preclinical work continues on an oral CDK2 program with Gilead [12][13] Investment Thesis - The investment thesis focuses on the execution of Kymera's pipeline in targeted protein degradation, particularly the progress of KT-621, which could positively impact stock performance [15]

Key Takeaways Viatris beat Q4 estimates with 57-cent EPS and $3.7B in revenue, up 5% year over year.VTRS saw 8% operational growth in Emerging Markets and Greater China, lifting Brands sales 8%.Viatris guided 2026 revenue to $14.4B-$14.9B and EPS of $2.33-$2.47 after FDA updates.Viatris Inc. (VTRS) delivered fourth-quarter 2025 adjusted earnings per share (EPS) of 57 cents, which beat the Zacks Consensus Estimate of 52 cents. The company recorded an adjusted EPS of 54 cents in the year-ago quarter.Total rev ...

Key Takeaways ALKS delivered Q4 earnings and revenue beat, though total sales fell 10.6% year over year.ALKS saw Lybalvi sales jump 22%, while manufacturing and royalty revenues sank 43% Y/Y in Q4.ALKS named Blair Jackson CEO from August 2026 and guided 2026 revenues to be $1.73-$1.84B.Alkermes plc (ALKS) reported adjusted earnings from continuing operations of 46 cents per share for the fourth quarter of 2025, which beat the Zacks Consensus Estimate of 43 cents. The company registered earnings of $1.04 per ...

Key Takeaways ADMA reported Q4 revenues of $139.2M, up 18%, with adjusted EPS rising to 21 cents.Asceniv sales jumped 51% in 2025 to $363M, fueling total revenue growth of 20%.ADMA guides 2026 revenues above $635M as yield-enhanced output boosts margins.ADMA Biologics (ADMA) reported fourth-quarter 2025 adjusted earnings per share (EPS) of 21 cents, (excluding stock-based compensation modifications, yield enhancement expense up, voluntary withdrawal and product replacements and non-recurring professional fe ...

Key Takeaways MIRM reported Q4 loss of 11 cents, but revenues beat estimates, rising 50% Y/Y to $148.9M.MIRM Q4 2025 sales were driven by Livmarli and newly acquired Cholbam and Ctexli products.MIRM guides 2026 net product sales of $630-$650M, eyes positive cash flow in 2027.Mirum Pharmaceuticals (MIRM) reported a loss of 11 cents per share in fourth-quarter 2025, against the Zacks Consensus Estimate of earnings of 2 cents. The company reported a loss of 49 cents per share in the year-ago quarter.Revenues i ...

Key Takeaways IRWD posted Q4 loss and revenue miss, with sales down 47% and shares sliding 11%.Ironwood's Linzess profit share declined 49% as U.S. net sales dropped 27% Y/Y in Q4 2025.IRWD reaffirmed 2026 revenue outlook of $450M-$475M and continues to see EBITDA above $300M.Ironwood Pharmaceuticals (IRWD) reported an adjusted loss of 1 cent per share for the fourth quarter of 2025, against the Zacks Consensus Estimate of earnings of 2 cents. The company had reported adjusted earnings of 1 cent per share i ...